High-density lipoprotein: why all the fuss?

被引：11

作者：

Mackness, Bharti

Mackness, Mike

机构：

[1] Pontech House, Stockport SK6 5EW, Cote Green Road, Marple Bridge

来源：

ANNALS OF CLINICAL BIOCHEMISTRY | 2009年 / 46卷

关键词：

CHOLESTEROL LEVELS; CORONARY ATHEROSCLEROSIS; ENDOTHELIAL-CELLS; HEART-DISEASE; HDL; TORCETRAPIB; PARAOXONASE-1; PARTICLES; WALL;

D O I：

10.1258/acb.2008.008133

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

100118 [医学信息学]; 100208 [临床检验诊断学];

摘要：

The current search for new treatments to combat coronary heart disease (CHD) is centred on increasing HDL-cholesterol. The failure of the CETP inhibitor torcetrapib may force a rethink. This perspective briefly reviews the antiatherosclerotic properties of HDL and ways HDL-cholesterol concentration can be raised, but argues - in light of the fact that HDIL-cholesterol concentration does not reflect the protective properties of HDL particles - that this approach is flawed and a different approach, targeting know antiatherosclerotic components of HDL, is required.

引用

收藏

页码：5 / 7

页数：3

相关论文

共 24 条

[1]

Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells [J].

Abderrahmani, A. ;

Niederhauser, G. ;

Favre, D. ;

Abdelli, S. ;

Ferdaoussi, M. ;

Yang, J. Y. ;

Regazzi, R. ;

Widmann, C. ;

Waeber, G. .

DIABETOLOGIA, 2007, 50 (06) :1304-1314

[2]

Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment [J].

Ansell, BJ ;

Navab, M ;

Hama, S ;

Kamranpour, N ;

Fonarow, G ;

Hough, G ;

Rahmani, S ;

Mottahedeh, R ;

Dave, R ;

Reddy, ST ;

Fogelman, AM .

CIRCULATION, 2003, 108 (22) :2751-2756

[3]

Effects of torcetrapib in patients at high risk for coronary events [J].

Barter, Philip J. ;

Caulfield, Mark ;

Eriksson, Mats ;

Grundy, Scott M. ;

Kastelein, John J. P. ;

Komajda, Michel ;

Lopez-Sendon, Jose ;

Mosca, Lori ;

Tardif, Jean-Claude ;

Waters, David D. ;

Shear, Charles L. ;

Revkin, James H. ;

Buhr, Kevin A. ;

Fisher, Marian R. ;

Tall, Alan R. ;

Brewer, Bryan .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122

[4]

Molecular mechanisms of reverse cholesterol transport [J].

Barter, PJ ;

Rye, KA .

CURRENT OPINION IN LIPIDOLOGY, 1996, 7 (02) :82-87

[5]

CHISOLM GM, 1996, ATHEROSCLEROSIS CORO, P129

[6]

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels [J].

Davidson, Michael H. ;

McKenney, James M. ;

Shear, Charles L. ;

Revkin, James H. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (09) :1774-1781

[7]

Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity [J].

de Souza, Juliana A. ;

Vindis, Cecile ;

Hansel, Boris ;

Negre-Salvayre, Anne ;

Therond, Patrice ;

Serrano, Carlos V., Jr. ;

Chantepie, Sandrine ;

Salvayre, Robert ;

Bruckert, Eric ;

Chapman, M. John ;

Kontush, Anatol .

ATHEROSCLEROSIS, 2008, 197 (01) :84-94

[8]

Beyond high-density lipoprotein cholesterol levels - Evaluating high-density lipoprotein function as influenced by novel therapeutic approaches [J].

deGoma, Emil M. ;

deGoma, Rolando L. ;

Rader, Daniel J. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (23) :2199-2211

[9]

FORREST MJ, 2008, BRIT J PHARMACOL, P229

[10]

HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND CARDIOVASCULAR-DISEASE - 4 PROSPECTIVE AMERICAN-STUDIES [J].

GORDON, DJ ;

PROBSTFIELD, JL ;

GARRISON, RJ ;

NEATON, JD ;

CASTELLI, WP ;

KNOKE, JD ;

JACOBS, DR ;

BANGDIWALA, S ;

TYROLER, HA .

CIRCULATION, 1989, 79 (01) :8-15